News & Updates

Repeat transarterial chemoembolization (TACE) is not recommended for patients with hepatocellular carcinoma (HCC) who have persistent liver function deterioration after initial TACE, particularly if they have suboptimal baseline liver function or excessive tumour burden, according to researchers from the Chinese University of Hong Kong (CUHK).

Combined use of sodium-glucose cotransporter 2 inhibitors (SGLT2i) and pioglitazone may be a potentially useful strategy to ameliorate metabolic dysfunction–associated steatohepatitis (MASH) in patients with type 2 diabetes (T2D), according to a real-world study conducted by researchers from the University of Hong Kong and Queen Mary Hospital (QMH).

Experts have proposed a subtle approach to diagnosing obesity that shifts the focus from BMI alone. Instead, they urged using other body fat measures such as waist circumference or direct fat mass measurement and signs and symptoms of ill health to confirm excess body fat.

Treatment with peginterferon (PegIFN) α-2b appears to inhibit the growth of and thyroid function in children with chronic hepatitis B (CHB), suggests a study.

A single tremelimumab regular interval durvalumab (STRIDE) provides survival benefits to Asian patients with unresectable hepatocellular carcinoma (HCC), as shown by the results of the HIMALAYA study.